Summary & Overview

HIV with Major Related Condition with MCC: Inpatient Reimbursement Overview

DRG 974 pertains to inpatient admissions for human immunodeficiency virus infection with a Major Complication or Comorbidity and encompasses cases with substantial clinical complexity. This grouping matters for inpatient reimbursement because the presence of a Major Complication or Comorbidity typically increases resource intensity and influences Medicare payment assignment.

HIV with Major Related Condition with MCCDRG HIV with Major Related Condition with MCCDRG 974Diagnosis-Related GroupInpatient ReimbursementMedicareInfectious DiseaseInternal MedicineHospital CodingOpportunistic Infection

DRG 974 Overview

DRG 974 covers inpatient stays for patients with human immunodeficiency virus infection accompanied by a Major Complication or Comorbidity, reflecting cases with significant clinical complexity such as severe opportunistic infections or organ dysfunction. This Diagnosis-Related Group affects Medicare payment because higher resource use and longer lengths of stay associated with Major Complication or Comorbidity influence the inpatient reimbursement assignment. Hospitals and coders must accurately capture principal and secondary diagnoses and any major complications or comorbidities to ensure correct grouping and payment. The category is clinically focused on managing advanced stages of human immunodeficiency virus illness with serious concurrent conditions.

Clinical Trials

Acute inpatient therapeutic trials focusing on management of life‑threatening opportunistic infections or severe HIV‑related complications in patients coded to this DRG. These studies enroll hospitalized adults with advanced HIV and a major related condition (for example, cryptococcal meningitis, severe Pneumocystis jirovecii pneumonia, disseminated mycobacterial infection, or severe organ dysfunction) to evaluate optimized antimicrobial regimens, adjunctive therapies, or intensive supportive care protocols. Results inform clinicians about efficacious inpatient strategies and help payers and hospitals anticipate resource intensity, length of stay, and high‑cost interventions required for this high‑acuity population.
Comparative effectiveness and antiretroviral management studies evaluating timing and selection of antiretroviral therapy in patients who present with a major related condition and MCC. These trials or observational cohorts study when to initiate or modify antiretroviral treatment around acute management of the major condition, comparing outcomes such as incident immune reconstitution inflammatory syndrome, mortality, and readmissions among different timing or regimen strategies. Findings are directly relevant to clinicians balancing short‑term infectious risk with long‑term HIV control, and to payers assessing cost‑effectiveness of inpatient versus expedited outpatient transitions of care.
Transitional care, readmission prevention, and long‑term outcomes studies that follow patients discharged from hospital after an acute HIV‑related major condition with MCC. These prospective cohorts or pragmatic trials test interventions such as enhanced discharge planning, linkage to outpatient HIV specialty care, integrated case management for comorbidities, and adherence support to reduce 30‑ and 90‑day readmissions, mortality, and cumulative costs. Evidence from these studies guides hospitals and payers on programs that improve continuity of care, reduce preventable reutilization, and address the complex social and medical needs typical of this DRG population.

Clinical Trials

Acute inpatient therapeutic trials focusing on management of life‑threatening opportunistic infections or severe HIV‑related complications in patients coded to this DRG. These studies enroll hospitalized adults with advanced HIV and a major related condition (for example, cryptococcal meningitis, severe Pneumocystis jirovecii pneumonia, disseminated mycobacterial infection, or severe organ dysfunction) to evaluate optimized antimicrobial regimens, adjunctive therapies, or intensive supportive care protocols. Results inform clinicians about efficacious inpatient strategies and help payers and hospitals anticipate resource intensity, length of stay, and high‑cost interventions required for this high‑acuity population.
Comparative effectiveness and antiretroviral management studies evaluating timing and selection of antiretroviral therapy in patients who present with a major related condition and MCC. These trials or observational cohorts study when to initiate or modify antiretroviral treatment around acute management of the major condition, comparing outcomes such as incident immune reconstitution inflammatory syndrome, mortality, and readmissions among different timing or regimen strategies. Findings are directly relevant to clinicians balancing short‑term infectious risk with long‑term HIV control, and to payers assessing cost‑effectiveness of inpatient versus expedited outpatient transitions of care.
Transitional care, readmission prevention, and long‑term outcomes studies that follow patients discharged from hospital after an acute HIV‑related major condition with MCC. These prospective cohorts or pragmatic trials test interventions such as enhanced discharge planning, linkage to outpatient HIV specialty care, integrated case management for comorbidities, and adherence support to reduce 30‑ and 90‑day readmissions, mortality, and cumulative costs. Evidence from these studies guides hospitals and payers on programs that improve continuity of care, reduce preventable reutilization, and address the complex social and medical needs typical of this DRG population.

OpenPayer

Summary & Overview

HIV with Major Related Condition with MCC: Inpatient Reimbursement Overview

DRG 974 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes